Table 1. Clinical characteristics of benign and malignant fGGOs before and after PSM.
| Characteristic | Before PSM |
After PSM |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 128) | Benign (n = 51) | Malignant (n = 77) | P | All (n = 82) | Benign (n = 41) | Malignant (n = 41) | P | |||
| Age, yrs | 56.6† (range: 18–79) | 53.8† (range: 18–77) | 58.7† (range: 33–79) | 0.078 | 54.4† (range: 18–79) | 55† (range: 18–77) | 54† (range: 33–79) | 0.817 | ||
| Smoking history, pack-yr | 7.8† (range: 0–60) | 9.7† (range: 0–60) | 6.6† (range: 0–60) | 0.587 | 5.9† (range: 0–60) | 9.3† (range: 0–60) | 2.5† (range: 0–60) | 0.173 | ||
| Time since smoking cessation, yr | 0.8† (range: 0–20) | 1.2† (range: 0–20) | 0.6† (range: 0–20) | 0.204 | 1.1† (range: 0–20) | 1.3† (range: 0–20) | 0.9† (range: 0–20) | 0.340 | ||
| Sex(%) | 0.149 | 0.659 | ||||||||
| Male | 62 | 48.4% | 29 | 33 | 41 | 50.0% | 22 | 19 | ||
| Female | 66 | 51.6% | 22 | 44 | 41 | 50.0% | 19 | 22 | ||
| Symptom | 0.007 | 0.372 | ||||||||
| Absent | 69 | 53.9% | 35 | 34 | 47 | 57.3% | 26 | 21 | ||
| Present | 59 | 46.1% | 16 | 43 | 35 | 42.7% | 15 | 20 | ||
| History of other lung diseases | 0.702 | 1.000 | ||||||||
| Absent | 121 | 94.5% | 49 | 72 | 80 | 97.6% | 40 | 40 | ||
| Present | 7 | 5.5% | 2 | 5 | 2 | 2.4% | 1 | 1 | ||
| History of lung cancer | 0.015 | 0.312 | ||||||||
| Absent | 112 | 87.5% | 40 | 72 | 72 | 87.8% | 34 | 38 | ||
| Present | 16 | 12.5% | 11 | 5 | 10 | 12.2% | 7 | 3 | ||
| History of other cancers | 0.001 | 0.198 | ||||||||
| Absent | 98 | 76.6% | 31 | 67 | 62 | 75.6% | 28 | 34 | ||
| Present | 30 | 23.4% | 20 | 10 | 20 | 24.4% | 13 | 7 | ||
| Family history of lung cancer | 0.682 | 0.999 | ||||||||
| Absent | 122 | 95.3% | 48 | 74 | 77 | 93.9% | 38 | 39 | ||
| Present | 6 | 4.7% | 3 | 3 | 5 | 6.1% | 3 | 2 | ||
PSM: propensity score matching.
†Values are given as the median fGGOs.